This is the authors' abstract. We don't add key points for this paper.
Triple-negative breast cancer (TNBC) is one of the most heterogeneous diseases in solid tumors and has limited therapeutic options. Due to the lack of appropriate targetable markers, the mainstay therapeutic strategy for patients with TNBC has been chemotherapy for the last several decades. Indeed, TNBC tumors have no expression of estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2 (HER2); therefore, they do not respond to hormone therapy and HER2-targeted therapy. In this review paper, the molecular heterogeneities, possible therapeutic targets, and recently approved and upcoming drugs for TNBC will be summarized.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ryu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: